PROTEIN BIOMARKERS OF LATE STAGE BREAST CANCER

摘要

This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non-aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as “companion diagnostic” proteins, wherein the differentially expressed proteins that are used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.

主权项

1. A method of diagnosing that a breast cancer as an early stage primary breast cancer (stage 0) or a late stage (stage 3) breast cancer comprising the steps of:
a) measuring the level of expression of at least one or more, at least two or more, at least 3 or more, or multiples and combinations of the proteins listed in Table 1 in a sample from a human patient, in which said sample comprises breast cancer tissue, breast cancer cells, or a bodily fluid such as blood or ascites fluid containing proteins from said patient's breast cancer said sample; and b) determining increased expression and/or decreased expression of said at least one or more, at least two or more, at least 3 or more, or multiples and combinations of the proteins listed in Table 1 in a late stage (stage 3) breast cancer as compared to expression levels of said at least one or more, at least two or more, at least 3 or more, or multiples and combinations of the proteins listed in Table 1 in early stage (stage 0) breast cancer indicating the potential that a primary breast cancer is more or less aggressive in said patient.